Osteoarthritis stem cell therapy

Application of adipose derived mesenchymal stem cells (Ad-MSC) in treating OSTeoarticular and Cartilage lesions

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN13337022

Enrollment

Registered

2017-02-24

Start date

2016-01-18

Completion date

Unknown

Last updated

2020-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis Musculoskeletal Diseases Knee osteoarthritis

Interventions

Participants undergo a complete physical examination including X-rays/MRI and biochemical laboratory tests. Participants also complete a specific questionnaire (International Knee Documentation Commit

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age 40-85 2. Knee osteoarthritis (radiological Kellgren and Lawrence grade II-IV) 3. Onset of symptoms for more than 6 months in the painful knee 4. Able to follow the instructions of the study 5. Signed an informed consent form

Exclusion criteria

Exclusion criteria: 1. Age less than 40 years or more than 85 years 2. Chondromatosis or villonodular synovitis of the knee 3. Recent trauma (<3 month) of the symptomatic knee 4. Infectious joint disease 5. Malignancy 6. Patients on anticoagulant therapy with PT ( < 0,70) or suffering from thrombocytopenia and/or coagulation disorder 7. Hypersensitivity to local anaesthetic

Design outcomes

Primary

Measure	Time frame
1. Pain in the knee is measured using the visual analogue scale (VAS) at the baseline, 3, 6 and 12 months 2. Function of the knee is measured using Knee Injury and Osteoarthritis Outcome Score (KOOS) at baseline, 3, 6 and 12 months	—

Secondary

Measure	Time frame
1. Matrix synthesis in the cartilage layer (glycosaminoglycan content) delayed gadolinium enhanced MRI (dGEMRIC) imaging technique is applied at the baseline, 3, 6 and 12 months. 2. Changes in IgG glycosylation associated with inflammatory processes analyses of IgG glycom from the blood plasma and synovial fluid (when available) is performed at baseline, 6 and 12 months 3. Subchondral bone edema, morphology of cartilage and soft tissues is measured by MRI scans at baseline and at 3, 6 and 12 months	—

Measure

Time frame

1. Matrix synthesis in the cartilage layer (glycosaminoglycan content) delayed gadolinium enhanced MRI (dGEMRIC) imaging technique is applied at the baseline, 3, 6 and 12 months. 2. Changes in IgG glycosylation associated with inflammatory processes analyses of IgG glycom from the blood plasma and synovial fluid (when available) is performed at baseline, 6 and 12 months 3. Subchondral bone edema, morphology of cartilage and soft tissues is measured by MRI scans at baseline and at 3, 6 and 12 months

—

Countries

Croatia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026